Transplant recipients experience limited prot

New research indicates that lung and heart transplant recipients experienced diminished and delayed antibody responses to the first two COVID-19 mRNA vaccine doses, but most developed significantly better responses following a third dose

Related Keywords

Boston ,Massachusetts ,United States ,America ,American ,Kathryn Bowman ,Zoef Weiss ,Rohan Singh ,Joshi Mathews ,Fadi Ghantous ,Gregoryd Lewis ,Camillen Kotton ,Isabel Neuringer ,Natasha Bitar ,Amy Li ,Marciab Goldberg ,Taryn Lipiner ,Jacobe Lemieux ,Anands Dighe ,Pierreo Ankomah ,Division Of Infectious Diseases ,Method Of Research ,Mendez National Institute Of Transplantation Foundation ,Research Institute ,Forum Infectious Diseases ,American Lung Association ,Harvard Medical School ,Initiative Special Research Award ,Clinical Research Award ,Massachusetts General Hospital ,Open Forum Infectious Diseases ,Infectious Diseases ,Harvard Medical ,Cystic Fibrosis ,Mendez National Institute ,Transplantation Foundation ,Massachusetts General ,General Hospital ,Mass General Research Institute ,Mass General ,World Report ,Best Hospitals ,Mass General Brigham ,Attenuated Antibody Responses ,Coronavirus Disease ,With Poor Cross Variant Neutralization ,Solid Organ Transplant Recipients ,Prospective Longitudinal ,